All Patients With GI Cancers Should Undergo NGS


The results of genetic testing could change a patient's treatment regimen.

Genetic alterations could mean different (and more effective) treatment choices for patients with gastrointestinal (GI) cancers, according to Tanios S. Bekaii-Saab, MD.

Bekaii-Saab, medical oncologist, and medical director of the Cancer Clinical Research Office, vice chair and section chief of Medical Oncology in the Department of Internal Medicine, at Mayo Clinic, said that all patients with GI cancers should undergo next-generation sequencing (NGS), at the very least.


The filed of cancer overall is moving toward more universal next-generation sequencing, and even in some instances, in our institution for example, we try to get even beyond NGS to more whole-genome [sequencing].

Every colon cancer patient, every biliary cancer patient, every gastric patient, and I would argue every [pancreatic] cancer patient, and every GI cancer patient should be screened for alterations through, at least, next-generation sequencing. Why is this important? Well, it's important because of a lot of reasons. One, what's approved, and two, what's being studied.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.